INT7457

Context Info Confidence 0.60 First Reported 1992 Last Reported 2005 Negated 0 Speculated 2 Reported most in Body Documents 3 Total Number 12 Disease Relevance 2.75 Pain Relevance 0.85

endoplasmic reticulum (Kcnma1) plasma membrane (Kcnma1)

Anatomy Link Frequency lung 2 myocytes 1 sensory nerves 1 C127 1 reticulum 1 Kcnma1 (Rattus norvegicus)

Pain Link Frequency Relevance Heat Inflammation 20 97.84 fibrosis 40 97.60 Calcium channel 2 95.88 agonist 10 92.80 tetrodotoxin 1 92.04 antagonist 2 90.88 ischemia 48 81.32 cerebral cortex 2 75.00 Glutamate 9 63.60 imagery 8 62.44

Disease Link Frequency Relevance Heat Inborn Genetic Diseases 8 99.76 Stress 64 99.20 Hypoxia 64 98.92 Cystic Fibrosis 40 98.16 INFLAMMATION 20 97.84 Pressure And Volume Under Development 216 96.68 Colitis 6 86.72 Inflammatory Bowel Disease 1 82.96 Cv Unclassified Under Development 48 81.32 Glioma 8 73.92

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Ryanodine, a blocker of the sarcoplasmic reticulum calcium-induced calcium release channel, was also without effect.

Localization (release) of channel in reticulum

1) Confidence 0.60 Published 1992 Journal Glia Section Abstract Doc Link 1349589 Disease Relevance 0 Pain Relevance 0.35

The excitatory responses of deflationary slowly adapting pulmonary stretch receptor (SAR) activity to lung deflation ranging from approximately -15 to -25 cm of H(2)O for approximately 5 s were examined before and after administration of flecainide, a Na(+) channel blocker, and K(+) channel blockers, such as 4-aminopyridine (4-AP) and tetraethylammonium (TEA).

Spec (examined) Localization (administration) of channel in lung

2) Confidence 0.42 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11805222 Disease Relevance 0 Pain Relevance 0

The excitatory responses of deflationary slowly adapting pulmonary stretch receptor (SAR) activity to lung deflation ranging from approximately -15 to -25 cm of H(2)O for approximately 5 s were examined before and after administration of flecainide, a Na(+) channel blocker, and K(+) channel blockers, such as 4-aminopyridine (4-AP) and tetraethylammonium (TEA).

Spec (examined) Localization (administration) of channel in lung

3) Confidence 0.42 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11805222 Disease Relevance 0 Pain Relevance 0

The vanilloid receptor subtype-1 (VR-1) is a cation channel located on the sensory nerves that, when stimulated, release proinflammatory peptides.

Localization (release) of channel in sensory nerves

4) Confidence 0.02 Published 2004 Journal J. Gastrointest. Surg. Section Abstract Doc Link 15531237 Disease Relevance 0.68 Pain Relevance 0.16

Maxi-anion channel as an ATP-releasing pathway

Localization (releasing) of channel

5) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0.33 Pain Relevance 0

The swelling-induced release of ATP from neonatal rat ventricular myocytes was sensitive to the anion channel blockers SITS and NPPB, suggesting an electrogenic mechanism of ATP release via an anion channel.

Localization (release) of channel in myocytes associated with pressure and volume under development

6) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0.63 Pain Relevance 0.11

The structural basis for channel-mediated ATP release remains obscure.

Localization (release) of channel

7) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0 Pain Relevance 0

Connexin as an ATP-releasing channel

Localization (releasing) of channel

8) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0.07 Pain Relevance 0.03

Thus, it is possible that Cx expression upregulates the activity of an ATP-releasing anion channel which is distinct from the Cx-hemichannel.

Localization (releasing) of channel

9) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0.25 Pain Relevance 0.06

Recent advances in crystallographic methods may provide us with a biophysically solid framework for understanding channel-mediated ATP release.

Localization (release) of channel

10) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0 Pain Relevance 0

CFTR as an ATP-releasing channel

Localization (releasing) of channel

11) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0.45 Pain Relevance 0.14

Cardiac ATP release and maxi-anion channel activity shared the same pharmacological profile and were sensitive to Gd3+ and arachidonic acid, which are the most effective blockers of maxi-anion channels in C127 cells [115, 213].

Localization (release) of channel in C127

12) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096548 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.